A Nature paper published April 8 by Su, Ashenhurst, Xu and colleagues at the 23andMe Research Institute reports a genome-wide association study of 27,885 participants who used GLP-1 receptor agonists. [1] The lead finding: a missense variant in the GLP1R gene (rs10305420) is associated with increased weight-loss efficacy. Carriers lost on average 0.76 kilograms more over a median eight months of treatment. [2] The paper's p-value reaches 2.9 × 10⁻¹⁰, which is genome-wide significance. The weekend's Reuters framing — a modest but significant effect — captures it. [3]

Side-effect genetics are the paper's second contribution. Variants in both GLP1R and GIPR are linked to nausea and vomiting. The GIPR association is drug-specific: it shows up in people using tirzepatide (Mounjaro, Zepbound) and not in people using semaglutide (Ozempic, Wegovy). [1] Carriers of one index variant were 83% more likely than non-carriers to vomit after taking tirzepatide. [3] The drug targets differ — tirzepatide is a GLP-1/GIP co-agonist and semaglutide is GLP-1 alone — so the finding is mechanistic, not methodological.

The cohort profile matters for the publication's limits. It is 82.4% female, median age 52, majority European ancestry, self-reported usage. The authors note the genetic effects on weight loss are small next to clinical predictors like baseline BMI and adherence. [2] The paper does not claim that genotype should guide prescription. It claims that the drug-target genes contribute to the variability clinicians have been observing since Ozempic's ascent. The 23andMe Total Health report rolling out to members this week is the commercial expression of the finding. The science is: GLP-1 receptors vary, and the variation shows up in the scale and in the bucket. [1]

-- KENJI NAKAMURA, Tokyo